amiloride has been researched along with Pulmonary Fibrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibouraadaten, S; Lison, D; Marbaix, E; Palmai-Pallag, M; Piret, JP; van den Brule, S; Vietti, G; Yakoub, Y | 1 |
| Alton, EW; Clarke, SW; Geddes, DM; Graham, A; Hasani, A; Hodson, ME; Marriott, C; Martin, GP | 1 |
1 trial(s) available for amiloride and Pulmonary Fibrosis
| Article | Year |
|---|---|
No added benefit from nebulized amiloride in patients with cystic fibrosis.
Topics: Administration, Intranasal; Adolescent; Adult; Amiloride; Child; Double-Blind Method; Epithelium; Female; Humans; Lung; Lung Volume Measurements; Male; Middle Aged; Mucociliary Clearance; Nebulizers and Vaporizers; Pulmonary Fibrosis | 1993 |
1 other study(ies) available for amiloride and Pulmonary Fibrosis
| Article | Year |
|---|---|
Towards predicting the lung fibrogenic activity of MWCNT: Key role of endocytosis, kinase receptors and ERK 1/2 signaling.
Topics: Amiloride; Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Endocytosis; ErbB Receptors; Female; Fibroblasts; MAP Kinase Signaling System; Mice; Nanotubes, Carbon; Phosphorylation; Platelet-Derived Growth Factor; Pulmonary Fibrosis; Receptors, Platelet-Derived Growth Factor; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2016 |